Endra Life Sciences Inc.
SEC CIK 1681682 · NDRA · last insider filing 2026-03-04
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Tokman Alexander Y | Director · Chief Executive Officer | filed 2017 - 2026 |
| Digiandomenico Anthony | Director | filed 2017 - 2026 |
| Harsh Michael | Director | filed 2017 - 2026 |
| Basenese Lou | Director | filed 2020 - 2026 |
| Michelon Francois Roger | Director · Chief Executive Officer | filed 2017 - 2023 |
| Gambhir Sanjiv Sam | Director | filed 2017 - 2020 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Jacroux Richard | Chief Financial Officer | filed 2024 - 2026 |
| Thornton Michael Milos | Chief Technology Officer | filed 2017 - 2023 |
| Pestrikova Irina | Senior Director, Finance | filed 2021 - 2023 |
| Maloberti Renaud Bertrand | Chief Commercial Officer | filed 2019 - 2022 |
| Wells David R. | Chief Financial Officer | filed 2017 - 2021 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.